InterMune (NASDAQ:ITMN) March 34 and 35 calls are active on total call volume 3,100 contracts (500 puts) on attracting takeover interest, Reuters says. March call option implied volatility is at 90, April is at 88, May and July is at 82; compared to its 26-week average of 90 according to Track Data. Active call volume…
Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume…
SiriusXM XM Holdings Inc (NASDAQ:SIRI) announced that it will air a special broadcast of “El Show de Piolin” on Saturday, March 8 during the upcoming blockbuster Pay-Per-View boxing event, “TOE TO TOE: Canelo vs. Angulo,” featuring Mexican boxing superstar “Canelo” Alvarez facing veteran fellow countryman Alfredo “El Perro” Angulo. Sirius XM Holdings Inc (NASDAQ:SIRI) stock…
Inovio Pharmaceuticals Inc (NYSEMKT:INO) raises $63 million, secures capital needs for near-term trial advancement and preparation to enter Phase lll studies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -1.96 percent to $3.51 yesterday on volume of INO 6.88million shares. The intra-day range of the stock was $3.50 to $3.71. Inovio Pharmaceuticals Inc (NYSEMKT:INO) has a market capitalization…
Officials with Zogenix Inc. (NASDAQ:ZGNX), the San Diego-based maker of Zohydro, did not return a message seeking comment about the drug. The company is marketing the drug as the first extended-release hydrocodone pain reliever without acetaminophen, which can cause liver failure if taken in excess. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -14.18% in last session…
On Wednesday, Jefferies raised it’s price target for SolarWinds (NYSE:SWI) to $57 from $51. In a research note issued by Aaron Schwartz, he indicated that the company’s cash flow potential remains underappreciated. The stock continues to be a stock favorite at Jefferies. Highlights of the note included: 20% license growth could serve as a baseline….
